FinTech
Recce Pharmaceuticals: Receives ‘intent to grant’ Patent Family 4 for anti-infectives
Recce Pharmaceuticals Receives ‘intent to grant’ Patent Family 4 for anti-infectivesRecce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its...
FinTech
Recce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial
Recce Pharmaceuticals Selects CMAX for phase I/II UTI clinical trialRecce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility...
FinTech
Recce Pharmaceuticals: Advances clinical programs in Q1 FY23
Recce Pharmaceuticals Advances clinical programs in Q1 FY23Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarter
RCE reported no...
FinTech
Recce Pharmaceuticals: Expands and accelerates clinical programs
Recce Pharmaceuticals Expands and accelerates clinical programsRecce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next...
FinTech
Recce Pharmaceuticals: Makes quarterly progress on R327
Recce Pharmaceuticals: Makes quarterly progress on R327Recce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during the June quarter
One of...
FinTech
Recce Pharmaceuticals: Receives positive safety data from second cohort of Phase I Clinical Trial
Recce Pharmaceuticals Receives positive safety data from second cohort of Phase I Clinical TrialRecce Pharmaceuticals (RCE) has released positive safety data from its...
FinTech
Recce Pharmaceuticals: Secures patent from E.U. regulator
Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations
This is the second time...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
